Table 1.
Time to Death Risk Reduction vs. Q1 | Time to First Major Cardiovascular Event Risk Reduction vs. Q1 |
Time to First Moderate/Severe Exacerbation Risk Reduction vs. Q1 | Time to First Severe Exacerbation Risk Reduction vs. Q1 | ||
---|---|---|---|---|---|
FEV1% Predicted | Q1 <53.5% | ||||
Q2 53.5 to 57.5% | 20% (4 to 34%) | 5% (−20 to 25%) | 11% (3 to 19%) | 10% (−5 to 23%) | |
Q3 57.5 to 61.6% | 28% (13 to 40%) | 15% (−8 to 33%) | 15% (7 to 22%) | 25% (12 to 37%) | |
Q4 61.6 to 65.8 | 23% (7 to 36%) | 9% (−15 to 28%) | 23% (16 to 30%) | 37% (25 to 47%) | |
Q5 ≥65.8% | 30% (15 to 42%) | 7% (−18 to 26%) | 27% (20 to 33%) | 40% (28 to 49%) | |
FVC % Predicted | Q1 <67.4% | ||||
Q2 67.4 to 73.6% | 14% (−4 to 29%) | 16% (−7 to 34%) | 2% (−8 to 10%) | 4% (−15 to 20%) | |
Q3 73.6 to 79.5% | 11% (−8 to 27%) | −4% (−30 to 17%) | −4% (−14 to 5%) | 0% (−20 to 17%) | |
Q4 79.5 to 87.6% | 14% (−4 to 29%) | 11% (−13 to 29%) | −6% (−17 to 3%) | −13% (−34 to 6%) | |
Q5 ≥87.6% | 21% (4 to 35%) | 21% (−1 to 38%) | −22% (−34 to −11%) | −28% (−52 to −8%) | |
FEV1/FVC | Q1 <0.51 | ||||
Q2 0.51 to 0.57 | 0% (−21 to 16%) | −7% (−36 to 16%) | 18% (11 to 25%) | 22% (9 to 33%) | |
Q3 0.57 to 0.62 | 7% (−12 to 24%) | −8% (−38 to 15%) | 28% (22 to 35%) | 39% (28 to 49%) | |
Q4 0.62 to 0.66 | 10% (−10 to 26%) | −12% (−43 to 12%) | 29% (22 to 35%) | 41% (29 to 50%) | |
Q5 ≥0.66 | −5% (−28 to 14%) | −18% (−50 to 8%) | 36% (30 to 42%) | 48% (37 to 57%) |
Notes: Results are from Cox Proportional Hazard models and are presented as risk reduction compared with Q1 quintile groups (with 95% confidence intervals). These are calculated as (1–hazard ratio) × 100. Negative % reductions indicate increase in risk, i.e., hazard ratio >1. Nominally significant differences are presented in bold (p<0.05, no adjustment for multiplicity).
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital capacity.